Cartesian Therapeutics
RNAC
98 hedge funds and large institutions have $245M invested in Cartesian Therapeutics in 2021 Q1 according to their latest regulatory filings, with 16 funds opening new positions, 38 increasing their positions, 27 reducing their positions, and 13 closing their positions.
288% more call options, than puts
Call options by funds: $5.25M | Put options by funds: $1.35M
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
59% more capital invested
Capital invested by funds: $154M → $245M (+$91.3M)
41% more repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 27
23% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 13
3% more funds holding
Funds holding: 95 → 98 (+3)
0.04% more ownership
Funds ownership: 1.56% → 1.61% (+0.04%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$6.35M |
| 2 |
N
Nuveen
Charlotte,
North Carolina
|
+$6.01M |
| 3 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$4.1M |
| 4 |
ACP
Acuta Capital Partners
Redwood City,
California
|
+$3.41M |
| 5 |
BlackRock
New York
|
+$3.18M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$4.96M |
| 2 |
BI
BVF Inc
San Francisco,
California
|
-$3.83M |
| 3 |
Renaissance Technologies
New York
|
-$2.84M |
| 4 |
6CM
683 Capital Management
New York
|
-$2.17M |
| 5 |
MP
Mangrove Partners
Greenwich,
Connecticut
|
-$2.14M |
RNAC Hedge Fund Activity: Q1 2021 in Review
98 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Cartesian Therapeutics (RNAC) for Q1 2021, worth a combined $245M — up 59% from $154M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new RNAC positions and 13 closed out — a net gain of 3 holders — while 38 added to existing stakes and 27 trimmed.
The largest buyer was Goldman Sachs, adding an estimated $6.35M. The largest seller was Armistice Capital, exiting entirely with an estimated $4.96M sold.
- 98 institutional investors held Cartesian Therapeutics (RNAC) as of Q1 2021, up from 95 in Q4 2020.
- Funds reported $245M of Cartesian Therapeutics stock for Q1 2021, up 59% quarter-over-quarter.
- 16 funds opened new Cartesian Therapeutics positions in Q1 2021 and 13 closed out, a net change of +3 holders.
- The largest Cartesian Therapeutics buyer in Q1 2021 was Goldman Sachs, an estimated $6.35M added.
- The largest Cartesian Therapeutics seller in Q1 2021 was Armistice Capital, an estimated $4.96M sold.
Based on aggregated 13F filings for Q1 2021.